Division of Infectious Diseases, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
Division of Infectious Diseases, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea.
J Microbiol Immunol Infect. 2023 Oct;56(5):1007-1015. doi: 10.1016/j.jmii.2023.07.010. Epub 2023 Jul 31.
The criteria for antibiotic failure in persistent Staphylococcus aureus bacteremia (SAB) are unclear, but treatment response and bacteremia duration are commonly used indicators of antibiotic failure. We evaluated the effects of treatment response and bacteremia duration on mortality in persistent SAB.
We retrospectively identified patients with persistent SAB in four university-affiliated hospitals between 2017 and 2021. Bacteremia duration was calculated from the first day of active antibiotic therapy, and persistent SAB was defined as bacteremia lasting for 2 or more days. Defervescence and Pitt bacteremia score (PBS) were used to evaluate treatment response at treatment day 4. The primary outcome was 30-day in-hospital mortality. Time-dependent multivariable Cox regression analysis and subgroup analysis according to methicillin resistance were performed.
A total of 221 patients was included in the study, and the 30-day in-hospital mortality was 28.5%. There was no significant difference in bacteremia duration between survived and deceased patients. Independent factors for mortality included age, Charlson comorbidity index, initial PBS, pneumonia, and removal of the eradicable focus. PBS at treatment day 4 ≥ 3 was the strongest risk factor (adjusted hazard ratio [HR] = 4.260), but defervescence was not. Bacteremia duration was not an independent factor except for 13 days or more of methicillin-resistant SAB (adjusted HR = 1.064).
In patients with persistent SAB, PBS at treatment day 4 was associated with 30-day in-hospital mortality rather than defervescence and bacteremia duration. The results of this study could help determine early intensified treatment strategies in persistent SAB patients.
耐甲氧西林金黄色葡萄球菌菌血症(SAB)持续存在时抗生素治疗失败的标准尚不明确,但治疗反应和菌血症持续时间通常是抗生素治疗失败的指标。我们评估了治疗反应和菌血症持续时间对耐甲氧西林金黄色葡萄球菌菌血症持续患者死亡率的影响。
我们回顾性地在 2017 年至 2021 年期间的四家大学附属医院中确定了耐甲氧西林金黄色葡萄球菌菌血症持续患者。菌血症持续时间从开始使用抗生素治疗的第一天开始计算,耐甲氧西林金黄色葡萄球菌菌血症持续被定义为持续存在 2 天或以上的菌血症。在治疗第 4 天,通过退热和 Pitt 菌血症评分(PBS)来评估治疗反应。主要结局为 30 天院内死亡率。进行了时间依赖性多变量 Cox 回归分析和根据耐甲氧西林金黄色葡萄球菌进行的亚组分析。
共纳入 221 例患者,30 天院内死亡率为 28.5%。存活患者和死亡患者的菌血症持续时间无显著差异。死亡率的独立因素包括年龄、Charlson 合并症指数、初始 PBS、肺炎和消除可根除的病灶。治疗第 4 天的 PBS≥3 是最强的危险因素(调整后的危险比[HR]为 4.260),但退热不是。除了耐甲氧西林金黄色葡萄球菌菌血症持续 13 天或以上的患者外,菌血症持续时间不是独立因素(调整后的 HR 为 1.064)。
在耐甲氧西林金黄色葡萄球菌菌血症持续存在的患者中,治疗第 4 天的 PBS 与 30 天院内死亡率相关,而与退热和菌血症持续时间无关。本研究的结果可以帮助确定耐甲氧西林金黄色葡萄球菌菌血症持续患者的早期强化治疗策略。